Screening and biological activities of pedopeptins, novel inhibitors of LPS produced by soil bacteria

Journal of Antibiotics

Volumn 67, Issue 3, 2014, Pages 237-242

  Kozuma, Shiho ^a   Hirota Takahata, Yuki ^a   Fukuda, Daisuke ^a   Kuraya, Nahoki ^a   Nakajima, Mutsuo ^a   Ando, Osamu ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

CD14; FRET; Lipopolysaccharide; Pedopeptin

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIUM LIPOPOLYSACCHARIDE; CD14 ANTIGEN; CYTOKINE; PEDOPEPTIN A; PEDOPEPTIN B; PEDOPEPTIN C; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ESCHERICHIA COLI; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; IC 50; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEDOBACTER; PRIORITY JOURNAL; SOIL MICROFLORA;

ANTI-BACTERIAL AGENTS; ANTIGENS, CD14; CULTURE MEDIA; CYTOKINES; DRUG DESIGN; ESCHERICHIA COLI; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; LIPOPOLYSACCHARIDES; MICROBIAL SENSITIVITY TESTS; PEDOBACTER; PEPTIDES, CYCLIC; SOIL; SOIL MICROBIOLOGY; U937 CELLS;

EID: 84897136479     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2013.121     Document Type: Article

References (24)

1. Hailman, E. et al. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J. Exp. Med. 179, 269-277 (1994
2. Bazil, V. et al. Biochemical characterization of a soluble form of the 53-kDa monocyte surface antigen. Eur. J. Immunol. 16, 1583-1589 (1986
3. Haziot, A. et al. The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J. Immunol. 141, 547-552 (1988
4. Hoshino, K. et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: Evidence for TLR4 as the Lps gene product. J. Immunol. 162, 3749-3752 (1999
5. Shimazu, R. et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med. 189, 1777-1782 (1999
6. Da Silva Correia, J., Soldau, K., Christen, U., Tobias, P. S. & Ulevitch, R. Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex: Transfer from CD14 to TLR4 and MD-2. J. Biol. Chem. 276, 21129-21135 (2001
7. Beutler, B. & Rietschel, E. T. Innate immune sensing and its roots: The story of endotoxin. Nat. Rev. Immunol. 3, 169-176 (2003
8. Wong, Y. N. et al. Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers. Innate. Immun. 14, 383-394 (2008
9. Stansly, P. G., Shepherd, R. G. & White, H. J. Polymyxin: A new chemotherapeutic agent. Bull. Johns Hopkins Hosp. 81, 43-54 (1947
10. Rifkind, D. Prevention by polymyxin B of endotoxin lethality in mice. J. Bacteriol. 93, 1463-1464 (1967
11. Jacobs, D. M. & Morrison, D. C. Inhibition of the mitogenic response to lipopolysaccharide (LPS) in mouse spleen cells by polymyxin B. J. Immunol. 118, 21-27 (1977
12. From, A. H., Fong, J. S. & Good, R. A. Polymyxin B sulfate modification of bacterial endotoxin: Effects on the development of endotoxin shock in dogs. Infect. Immun. 23, 660-664 (1979
13. Vinnicombe, J. & Stamey, T. A. The relative nephrotoxicities of polymyxin B sulfate, sodium sulfomethyl-polymyxin B, sodium sulfomethyl-colistin (colymycin), and neomycin sulfate. Invest. Urol. 6, 505-519 (1969
14. Mathis, G. Rare earth cryptates and homogeneous fluoroimmunoassays with human sera. Clin. Chem. 39, 1953-1959 (1993
15. Hirota-Takahata, Y. et al. Pedopeptins, novel inhibitors of LPS: Taxonomy of producing organism, fermentation, isolation, physicochemical properties and structural elucidation. J. Antibiot. (doi:10.1038/ja.2013.122
16. Huber, M. et al. R-form LPS, the master key to the activation of TLR4/MD-2-positive cells. Eur. J. Immunol. 36, 710-711 (2006
17. Gangloff, S. C., Hijiya, N., Haziot, A. & Goyert, S. M. Lipopolysaccharide structure influences the macrophage response via CD14-independent and CD14-dependent pathways. Clin. Infect. Dis. 28, 491-496 (1999
18. Bryant, C. E. et al. The cellular Toll-like receptor 4 antagonist E5531 can act as an agonist in horse whole blood. Vet. Immunol. Immunopathol. 116, 182-189 (2007
19. Zavascki, A. P. et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin. Infect. Dis. 15, 1298-1304 (2008
20. Mingeot-Leclercq, M. P., Tulkens, P. M., Denamur, S., Vaara, T. & Vaara, M. Novel polymyxin derivatives are less cytotoxic than polymyxin B to renal proximal tubular cells. Peptides 35, 248-252 (2012
21. Vaara, M., Sader, S. S., Rhomberg, P. R., Jones, R. N. & Vaara, T. Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens. J. Antimicrob. Chemother. 68, 636-639 (2013
22. Tamaki, M. et al. Polycationic gramicidin S analogues with both high antibiotic activity and very low hemolytic activity. Chem. Pharm. Bull. 60, 1134-1138 (2012
23. Hoess, A., Watson, S., Siber, G. R. & Liddington, R. Crystal structure of an endotoxinneutralizing protein from the horseshoe crab, Limulus anti-LPS factor, at 1.5A° ́ resolution. EMBO J. 12, 3352-3356 (1993
24. National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically, 5th ed., approved standard M7-A5 (NCCLS, Wayne, PA, USA, 2000